BIOMEDICAL DEVICE TO REMOVE ANTIA AND ANTIB ANTIBODIES

去除 ANTIA 和 Antib 抗体的生物医学设备

• 批准号: 2713491
• 负责人: TERRY M SCHAACK
• 金额: $ 10万
• 依托单位: ADVANCED EXTRAVASCULAR SYSTEMS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2713491
• 关键词: biomedical equipment development; blood group antigens; blood treatment; clinical biomedical equipment; clinical research; hollow fiber separation technique; human subject; isoantibody; kidney transplantation; method development

DESCRIPTION: (Adapted from the applicant's abstract) Removal of anti-A and anti-B antibodies from individuals should allow for renal organ transplantation without the restriction of ABO matching. The proposed device would accomplish this in a simple, highly biocompatible way, and with greater efficacy than other methods. This device consists of a hollow fiber filter system similar to traditional renal dialysis with synthetic blood group A and B substances attached to the lumenal surfaces. The ABO incompatible recipient would have their blood passed through the filter in a similar fashion to routine renal dialysis. Anti-A and anti-B antibodies will bind to the blood group A and B substances lining the lumenal surface of the filter. If high levels of anti-A and anti-B antibodies are [lowered to 1:2 level] in the peritransplant period, hyper- acute rejection can be eliminated and graft survival can be accomplished. The advantage of this technique included the increased biocompatibility achieved by the removal of antibody from whole blood as opposed to plasmapheresis followed by treatment with beaded columns and additionally the unique flow characteristics of hollow fibers allow for increased removal of antibodies via ultrafiltration. The device would increase the pool of living related and unrelated donors. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人的摘要）抗 A 的去除 和来自个体的抗 B 抗体应允许肾器官 移植不受ABO血型配型限制。 拟议的 设备将以简单、高度生物相容的方式实现这一点，并且 比其他方法更有效。 该设备由一个 类似于传统肾透析的中空纤维过滤系统 附着在管腔表面的合成血型 A 和 B 物质。 ABO 不相容的接受者的血液将通过 以与常规肾透析类似的方式进行过滤。 抗A和抗B 抗体会与 A 型血和 B 型血的物质结合 过滤器的内腔表面。 如果抗 A 和抗 B 水平较高 抗体在围移植期[降低至1:2水平]，超 可以消除急性排斥反应并实现移植物存活。 该技术的优点包括提高生物相容性 通过从全血中去除抗体来实现，而不是 血浆置换，然后用珠状柱处理，另外 中空纤维独特的流动特性允许增加 通过超滤去除抗体。该装置将增加 活着的相关和无关捐赠者库。 拟议的商业应用：不可用